Precision BioSciences, Inc. announced on May 7, 2025, the presentation of initial safety data from the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV at the European Association for the Study of the Liver (EASL) Congress.
The initial safety dataset from the first three participants, who received two of three planned dose administrations at the lowest dose level (0.2 mg/kg), indicated that PBGENE-HBV was well-tolerated upon repeat dosing. No dose-limiting toxicities, serious adverse events, or clinically significant laboratory abnormalities were observed.
All adverse events were mild (grade 1 or 2) and transient, with no cumulative adverse events after the second dose. These findings support the translation of preclinical pharmacokinetic and safety data into the clinic and endorse pre-planned repeat dosing and dose escalation for PBGENE-HBV, with further updates on antiviral efficacy expected throughout 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.